ORIGINAL_ARTICLE
Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography
Prostate cancer remains a major public health problem worldwide. Imaging plays an important role in the assessment of disease at all its clinical phases, including staging, restaging after definitive therapy, evaluation of therapy response, and prognostication. Positron emission tomography with a number of biologically targeted radiotracers has been demonstrated to have potential diagnostic and prognostic utility in the various clinical phases of this prevalent disease. Given the remarkable biological heterogeneity of prostate cancer, one major unmet clinical need that remains is the non-invasive imaging-based characterization of prostate tumors. Accurate tumor characterization allows for image-targeted biopsy and focal therapy as well as facilitates objective assessment of therapy effect. PET in conjunction with radiotracers that track the thymidine salvage pathway of DNA synthesis may be helpful to fulfill this necessity. We review briefly the preclinical and pilot clinical experience with the two major cellular proliferation radiotracers, [18F]-3’-deoxy-3’-fluorothymidine and [18F]-2’-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil in prostate cancer.
https://aojnmb.mums.ac.ir/article_3873_1170da7a82dccd551aba219deb3e37d7.pdf
2015-07-01
72
76
10.7508/aojnmb.2015.02.001
Prostate
Cancer
Proliferation
PET
Hossein
Jadvar
jadvar@med.usc.edu
1
Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
LEAD_AUTHOR
Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol. 2012; 199:278-91.
1
Yu CY, Desai B, Ji L, Groshen S, Jadvar H. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging. 2014; 4:580-601.
2
Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am. 2005; 43:153-67.
3
Couturier O, Leost F, Campone M, Cartlier T, Chatal JF, Hustinx R. Is 3’-deoxy-3’-[18F]fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after [18F]-FDG? Bull Cancer. 2005; 92:789-98.
4
Nimmagadda S, Shields AF. The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Rev. 2008; 27:575- 87.
5
Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008; 49 Suppl 2:64S-80S.
6
Tehrani OS, Shields AF. PET imaging of proliferation with pyrimdines. J Nucl Med. 2013; 54:903-12.
7
Shields AF, Mankoff D, Graham MM, Zheng M, Kozawa SM, Link JM, et al. Analysis of 2-carbon-11- thymidine blood metabolites in PET imaging. J Nucl Med. 1996; 37:290-6.
8
Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998; 39:1757-62.
9
Mankoff D, Shields AF, Link JM, Graham MM, Muzi M, Pterson LM, et al. Kinetic analysis of 2-[11C] thymidine PET imaging studies: validation studies. J Nucl Med. 1999; 40:614-24.
10
Mankoff DA, Shield AF, Graham MM, Link JM, Eary JF, Krohn KA. Kinetic analysis of 2-[carbon- 11] thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med. 1998; 39:1043-55.
11
Shields AF, Grierson JR, Muzik O, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, et al. Kinetics of 3’-deoxy-3’-[F- 18]fluorothymidine uptake and retention in dogs. Mol Imaging Biol. 2002 4:83-9.
12
Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, et al. A simplified analysis of [18F]3’- deoxy-3’-fluorthymidine metabolism and retention. Eur J Nucl Med Mol Imaging. 2005; 32:1269-75.
13
Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stananoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F- 18]FLT and positron emission tomography. Nat Med. 1998; 4:1334-6.
14
Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy- 3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27:143-56.
15
Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. 18F-fluorothymidine radiationdosimetry in human PET imaging studies. J Nucl Med. 2003; 44:1482-8.
16
Kukuk D, Reischl G, Raguin O, Wiehr S, Judenhofer MS, Calaminus C, et al. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models. J Nucl Med. 2011; 52:1654-63.
17
Oyama N, Ponde D, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen dependent prostate tumor model by measuring tumor proliferation. J Nucl Med. 2004; 45:519-25.
18
Oyama N, Hasegawa Y, Kiyono Y, Kobayashi M, Fujibayashi Y, Ponde DE, et al. Early response assessment in prostate carcinoma by 18F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumor models. Eur J Nucl Med Mol Imaging. 2011; 38:81-9.
19
Fanucchi MP, Leyland-Jones B, Young CW, Burchenal JH, Watanabe KA, Fox JJ. Phase I trial of 1-(2’-deoxy- 2’-fluoro-1-beta-D-arabinofuranosyl)- 5-methyluracil (FMAU). Cancer Treat Rep. 1985; 69:55-9.
20
Tehrani OS, Douglas KA, Lawhorn-Crews JM, Shields AF. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging. 2008; 35:1480-8.
21
Conti PS, Alauddin MM, Fissekis JR, Schmall B, Watanabe KA. Synthesis of 2'-fluoro-5-[11C]- methyl-1-beta-D-arabinofuranosyluracil ([11C]- FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol. 1995; 22:783-9.
22
Bading JR, Shahinian AH, Bathija P, Conti PS.Pharmacokinetics of the thymidine analog 2'-fluoro-5-[(14)C]-methyl-1-beta-D-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells. Nucl Med Biol 2000; 27:361-8.
23
Wang H, Oliver P, Nan L, Wang S, Wang Z, Rhie JK, et al. Radiolabeled 2'-fluorodeoxyuracil-beta- D-arabinofuranoside (FAU) and 2'-fluoro-5- methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemo ther Pharmacol. 2002; 49:419-24.
24
Lu L, Samuelsson L, Bergstrom M, Sato K, Fasth KJ, Langstrom B. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med. 2002; 43:1688-98.
25
Mangner TJ, Klecker RW, Anderson L, Shields AF. Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F] FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. Nucl Med Biol. 2003; 30(3):215-24.
26
de Vries EF, van Waarde A, Harmsen MC, Mulder NH, Vaaburg W, Hospers GA. [(11)C]FMAU and [(18)F]FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. Nucl Med Biol. 2000; 27:113-9.
27
Alauddin MM, Shahinian A, Gordon EM, Conti PS. Evaluation of 2’-deoxy-2’- fluoro-5-methyl-1-beta- D-arabinofurasyluracil as a potential gene imaging agent for HSV-tk expression in vivo. Mol Imaging. 2002; 1:74-81.
28
Alauddin MM, Shahinian A, Park R, Tohme M, Fissekis JD, Conti PS. Synthesis and evaluation of 2’-deoxy-2’-18F-fluoro-5-fluoro-1-beta-D-arabinofuranosyluracil as a potential PET imaging agent for suicide gene expression. J Nucl Med. 2004; 45:2063-9.
29
Kang KW, Min JJ, Chen X, Gambhir SS. Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H] PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type I thymidine kinase in cell culture. Mol Imaging Biol. 2005; 7:296-303.
30
Li Z, Cai H, Conti PS. Automated synthesis of 2’-deoxy-2’-[18F]fluoro-5-methyl- 1-b-D-arabinofuranosyluracil ([18F]-FMAU) using a one reactor radiosynthesis module. Nucl Med Biol. 2011; 38:201-6.
31
Bading JR, Shahinian AH, Vail A, Bathija P, Koszalka GW, Koda RT, et al. Pharmacokinetics of the thymidine analog 2’-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor bearing rats. Nucl Med Biol. 2004; 31:407-18.
32
Conti PS, Bading JR, Mouton PP, Links JM, Alauddin MM, Fissekis JD, et al. In vivo measurement of cell proliferation in canine brain tumor using C-11- labeled FMAU and PET. Nucl Med Biol. 2008; 35(1):131-41.
33
Tehrani OS, Muzik O, Heilbrun LK, Douglas KA, Lawhorn-Crews JM, Sun H, et al. Tumor imaging using 1-(2’-deoxy-18Ffluoro-beta-D-arabinofuranosyl) thymine and PET. J Nucl Med. 2007; 48:1436-41.
34
Nishii R, Volgia AY, Mawlawi O, Mukhopadhyay U, Pal A, Bommann W, et al. Evaluation of 2’-deoxy-2’-[(18)F]fluoro-5- methyl-1-beta-L:- arabinofuranosyluracil ([(18)F]-L:-FMAU) as a PET imaging agent for cellular proliferation: comparison with [(18)F]-D:-FMAU and [(18)F]FLT. Eur J Nucl Med Mol Imaging. 2008; 35:990-8.
35
Sun H, Mangner TJ, Collins JM, Muzik O, Douglas K, Shields AF. Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med 2005; 46(2):292-6.
36
Shields AF. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol. 2006; 8:141-50.
37
Jadvar H, Yap LP, Park R, Li Z, Chen K, Hughes L, et al. [18F]-2’-fluoro-5-methyl-1-beta- Darabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. Mol Imaging. 2012; 11(5):426-32.
38
Doeg KA, Polomski LL, Doeg LH. Androgen control of mitochondrial and nuclear DNA synthesis in male sex accessory tissue of castrate rats. Endocrinology. 1972; 90:1633-8.
39
Sun H, Sloan A, Mangner TJ, Vaishamayan U, Muzik O, Collins JM, et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005; 32:15-22.
40
Alauddin MM, Shahinian A, Gordon EM, Conti PS. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1- tk expression in a human breast cancer model. Mol Imaging. 2004; 3:76-84.
41
Cai H, Li Z, Conti PS. The improved syntheses of 5-substituited 2’-[18F]fluoro-2’-deoxy-arabinofuranosyluracil derivatives ([18F] FAU, [18F] FEAU, [18F] FFAU, [18F] FCAU, [18F] FBAU and [18F] FIAU) using a multistep one-pot strategy. Nucl Med Biol. 2011; 38:659-66.
42
ORIGINAL_ARTICLE
Usefulness of an Automatic Quantitative Method for Measuring Regional Cerebral Blood Flow Using 99mTc Ethyl Cysteinate Dimer Brain Uptake Ratio
Objective(s): Improved brain uptake ratio (IBUR), employing 99mTc-ethyl cysteinate dimer (99mTc-ECD), is an automatic non-invasive method for quantitatively measuring regional cerebral blood flow (rCBF). This method was developed by the reconstruction of the theory and linear regression equation, based on rCBF measurement by H215O positron emission tomography. Clarification of differences in rCBF values obtained by Patlak plot (PP) and IBUR method is important for clinical diagnosis during the transition period between these methods. Our purpose in this study was to demonstrate the relationship between rCBF values obtained by IBUR and PP methods and to evaluate the clinical applicability of IBUR method. Methods: The mean CBF (mCBF) and rCBF values in 15 patients were obtained using the IBUR method and compared with PP method values. Results: Overall, mCBF and rCBF values, obtained using these independent techniques, were found to be correlated (r=0.68). The mCBF values obtained by the IBUR method ranged from 18.9 to 44.9 ml/100g/min, whereas those obtained by the PP method ranged from 34.7 to 48.1 ml/100g/min. The rCBF values obtained by the IBUR method ranged from 16.3 to 60.2 ml/100g/min, whereas those obtained by the PP method were within the range of 26.7-58.8 ml/100g/min. Conclusion: The ranges of mCBF and rCBF values, obtained by the IBUR method, were approximately 60% lower than those obtained by the PP method; therefore, this method can be useful for diagnosing lower flow area. Re-analysis of prior PP data, using the IBUR method, could be potentially useful for the clinical follow-up of rCBF.
https://aojnmb.mums.ac.ir/article_3842_c454e5013b219c26002438313a1c49ee.pdf
2015-07-01
77
82
10.7508/aojnmb.2015.02.002
rCBF
99mTc-ECD
brain uptake
Patlak plot
SPECT
Rieko
Nagaoka
nagaoka@kyumed.jp
1
Department of Radiology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukoka, Japan
LEAD_AUTHOR
Asato
Ofuji
asiato2011@yahoo.co.jp
2
Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan
AUTHOR
Kosuke
Yamashita
ky12061783@yahoo.co.jp
3
Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan
AUTHOR
Taeko
Tomimatsu
taekotomi504@kyumed.jp
4
Department of Radiology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukoka, Japan
AUTHOR
Shinnichi
Orita
5
Department of Radiology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukoka, Japan
AUTHOR
Akihiro
Takaki
taakihiro@ffri.co.jp
6
Fujifilm RI Pharma Co., Ltd., Tokyo, Japan
AUTHOR
Yoshikazu
Uchiyama
y_uchi@kumamoto-u.ac.jp
7
Department of Medical Imaging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
AUTHOR
Shigeki
Ito
shigekii@kumamoto-u.ac.jp
8
Department of Medical Imaging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
AUTHOR
Newberg AB, Wintering N, Khalsa DS, Roggenkamp H, Waldman MR. Meditation effects on cognitive function and cerebral blood flow in subjects with memory loss: a preliminary study. J Alzheimers Dis. 2010;20(2):517-26.
1
Yonekura Y, Ishizu K, Okazawa H, Tanaka F, Hattori N, Sadato N et al. Simplified quantification of regional cerebral blood flow with 99mTc-ECD SPECT and continuous arterial blood sampling. Ann Nucl Med. 1996; 10(2):177-83.
2
Matsuda H, Yagishita A, Tsuji S, Hisada K. A quantitative approach to technetium-99m ethyl cysteinate dimmer: a comparison with technetium- 99m hexamethyl propylene amine oxime. Eur J Nucl Med. 1995; 22:633-7.
3
Ishizu K, Yonekura Y, Magata Y, Okazawa H, Fukuyama H, Tanaka F, et al. Extraction and retention of technetium-99m-ECD in human brain: dynamic SPECT and oxygen-15-water PET studies. J Nucl Med. 1996; 37(10): 1600-4.
4
Tsuchida T, Sadato N, Yonekura Y, Yamamoto K, Waki A, Sugimoto K, et al. Quantification of regional cerebral blood flow with continuous infusion of technetium-99m-ethyl cystemate dimer. J Nucl Med. 1997; 38: 1699-702.
5
Miyazaki Y, Kinuya S, Hashimoto M, Satake R, Inoue H, Shio- zaki J, et al. Brain uptake ratio as an index of cerebral blood flow obtained with 99mTc-ECD. Kaku Igaku. 1997; 34(1): 49–52.
6
Odano I, Ohkubo M, Yokoi T. Noninvasive quantification of cerebral blood flow using 99mTc- ECD and SPECT. J Nucl Med. 1999; 40(10): 1737-44.
7
Ito S, Tkaki A, Inoue S, Tomiguchi S, Shiraisgi S, Akiyama Y, et al. Improvement of the 99mTc-ECD brain uptake ratio (BUR) method for measurement of cerebral blood flow. Ann Nucl Med. 2012; 26(4): 351–8.
8
Inoue S, Kabuto T, Masunaga S, Souma T, Takaki A, Hosoya T, et al. Determination of the optimal ROI setting position of the input function for the ⁹⁹mTc-ethyl cysteinate dimmer brain uptake ratio method. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2012; 68(3): 269-76.
9
Osanai S, Inamura T, Yanaoka H, FukudaI, Minakawa M, Fukui K. Numerical Simulation of Flow in Aortic Arch under Extracorporeal Circulation. J Jpn Coll Angiol. 2008; 48: 313–8.
10
Minakawa M, Fukuda I, Yamazaki J, Fukui, K, Yanaoka, H, Inamura, T. Effect of cannula shape on aortic wall and flow turbulence: hydrodynamic study during extracorporeal circulation in mock thoracic aorta. Artif Organs. 2007; 31: 880-6.
11
Masunaga S, Uchiyama Y, Ofuji A, Nagaoka R, Tomimatsu T, Iwata T, et al. Development of an automatic ROI setting program for input function determination 99mTc-ECD non-invasive cerebral blood flow quantification. Phys Med. 2014; 30:513-21.
12
Takeuchi R, Yonekura Y, Matsuda H, Konishi J. Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET. Eur J Nucl Med Mol Imaging. 2002; 29:331-41.
13
Matsuda H, Tsuji S, Shuke N, Sumiya H, Tonami N, Hisada K. Noninvasive measurementsof regional cerebral blood flow using technetium-99m hexamethylpropylene amine oxime. Eur J Nucl Med. 1993, 20: 39l-401.
14
Lassen NA, Andersen AR, Friberg L, Paulson OB. The retention of [99mTc]-d,l-HM-PAO in the human brain after intracarotid bolus injection: a kinetic analysis. J Cereb Blood Flow Metab. 1988; 8(6):13-22.
15
ORIGINAL_ARTICLE
Importance of defect detectability in Positron Emission Tomography imaging of abdominal lesions
Objective(s): This study was designed to assess defect detectability in positron emission tomography (PET) imaging of abdominal lesions. Methods: A National Electrical Manufactures Association International Electrotechnical Commission phantom was used. The simulated abdominal lesion was scanned for 10 min using dynamic list-mode acquisition method. Images, acquired with scan duration of 1-10 min, were reconstructed using VUE point HD and a 4.7 mm full-width at half-maximum (FWHM) Gaussian filter. Iteration-subset combinations of 2-16 and 2-32 were used. Visual and physical analyses were performed using the acquired images. To sequentially evaluate defect detectability in clinical settings, we examined two middle-aged male subjects. One had a liver cyst (approximately 10 mm in diameter) and the other suffered from pancreatic cancer with an inner defect region (approximately 9 mm in diameter). Results: In the phantom study, at least 6 and 3 min acquisition durations were required to visualize 10 and 13 mm defect spheres, respectively. On the other hand, spheres with diameters ≥17 mm could be detected even if the acquisition duration was only 1 min. The visual scores were significantly correlated with background (BG) variability. In clinical settings, the liver cyst could be slightly visualized with an acquisition duration of 6 min, although image quality was suboptimal. For pancreatic cancer, the acquisition duration of 3 min was insufficient to clearly describe the defect region. Conclusion: The improvement of BG variability is the most important factor for enhancing lesion detection. Our clinical scan duration (3 min/bed) may not be suitable for the detection of small lesions or accurate tumor delineation since an acquisition duration of at least 6 min is required to visualize 10 mm lesions, regardless of reconstruction parameters. Improvements in defect detectability are important for radiation treatment planning and accurate PET-based diagnosis.
https://aojnmb.mums.ac.ir/article_3590_57e46c85097f4a4244aac19df426d456.pdf
2015-07-01
83
90
10.7508/aojnmb.2015.02.003
Positron Emission Tomography
defect detectability
abdominal lesion
Shozo
Yamashita
y.shozo57@gmail.com
1
Division of Radiology, Public Central Hospital of Matto Ishikawa, Hakusan, Japan
AUTHOR
Kunihiko
Yokoyama
yokoyama@mattohp.com
2
PET Imaging Center, Public Central Hospital of Matto Ishikawa, Hakusan, Japan
AUTHOR
Masahisa
Onoguchi
onoguchi@staff.kanazawa-u.ac.jp
3
Department of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
LEAD_AUTHOR
Haruki
Yamamoto
h-yamamoto@mattohp.jp
4
Division of Radiology, Public Central Hospital of Matto Ishikawa, Hakusan, Japan
AUTHOR
Tetsu
Nakaichi
tt_nakaichi@yahoo.co.jp
5
Division of Radiology, Public Central Hospital of Matto Ishikawa, Hakusan, Japan
AUTHOR
Shiro
Tsuji
tsujisss@mattohp.com
6
PET Imaging Center, Public Central Hospital of Matto Ishikawa, Hakusan, Japan
AUTHOR
Kenichi
Nakajima
nakajima@med.kanazawa-u.ac.jp
7
Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan
AUTHOR
Erdi YE, Nehmeh SA, Mulnix T, Humm JL, Watson CC. PET performance measurements for an LSO-based combined PET/CT scanner using the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med. 2004; 45(5):813-21.
1
Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med. 2005; 46(12):2083-91.
2
Matsumoto K, Kitamura K, Mizuta T, Tanaka K, Yamamoto S, Sakamoto S, et al. Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. J Nucl Med. 2006;47(1):83-90.
3
Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 2004;45(5):797-801.
4
Visvikis D, Cheze-LeRest C, Costa DC, Bomanji J, Gacinovic S, Ell PJ. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. Eur J Nucl Med. 2001; 28(9):1326-35.
5
Tatsumi M, Clark PA, Nakamoto Y, Wahl RL. Impact of body habitus on quantitative and qualitative image quality in whole-body FDG-PET. Eur J Nucl Med Mol Imaging. 2003; 30(1):40-5.
6
Nagaki A, Onoguchi M, Matsutomo N. Patient weight-based acquisition protocols to optimize (18) F-FDG PET/CT image quality. J Nucl Med Technol. 2011;39(2):72-6.
7
Fukukita H, Suzuki K, Matsumoto K, Terauchi T, Daisaki H, Ikari Y, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 2.0. Ann Nucl Med. 2014; 28(7):693-705
8
Zheng Y, Sun X, Wang J, Zhang L, DI X, Xu Y. FDG-PET/ CT imaging for tumor staging and definition of tumor volumes in radiation treatment planning in non-small cell lung cancer. Oncol Lett. 2014;7(4):1015- 20.
9
Riou O, Serrano B, Azria D, Paulmier B, Villeneuve R, Fenoglietto P, et al. Integrating respiratory-gated PET-based target volume delineation in liver SBRT planning, a pilot study. Radiat Oncol. 2014;9:127.
10
Okubo M, Nishimura Y, Nakamatsu K, Okumura M, Shibata T, Kanamori S, et al. Static and moving phantom studies for radiation treatment planning in a positron emission tomography and computed tomography (PET/CT) system. Ann Nucl Med. 2008; 22(7):579-86.
11
Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133(5):515-6.
12
Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol. 1991;173(1):25-9.
13
Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg. 2001; 234(5):675-80.
14
Lin CY, Chen HY, Ding HJ, Yen KY, Kao CH. FDG PET or PET/CT in evaluation of renal angiomyolipoma. Korean J Radiol. 2013;14(2):337-42.
15
Metser U, Miller E, Kessler A, Lerman H, Lievshitz G, Oren R, et al. Solid splenic masses: evaluation with 18F-FDG PET/CT. J Nucl Med. 2005;46(1):52-9.
16
Mananga ES, El Fakhri G, Schaefferkoetter J, Bonab AA, Ouyang J. Myocardial defect detection using PET-CT: phantom studies. PLoS One. 2014 5;9(2): e88200.
17
Tang J, Rahmim A, Lautamäki R, Lodge MA, Bengel FM, Tsui BM. Optimization of Rb-82 PET acquisition and reconstruction protocols for myocardial perfusion defect detection. Phys Med Biol. 2009; 54(10):3161-71.
18
Matsunari I, Yoneyama T, Kanayama S, Matsudaira M, Nakajima K, Taki J, et al. Phantom studies for estimation of defect size on cardiac (18)F SPECT and PET: implications for myocardial viability assessment. J Nucl Med. 2001; 42(10):1579-85.
19
Baiocchi GL, Portolani N, Bertagna F, Gheza F, Pizzocaro C, Giubbini R, et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results. J Exp Clin Cancer Res. 2008; 27:10.
20
Hong HS, Yun M, Cho A, Choi JY, Kim MJ, Kim KW, et al. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm. Clin Nucl Med. 2010; 35(10):776-9.
21
Takanami K, Hiraide T, Tsuda M, Nakamura Y, Kaneta T, Takase K, et al. Additional value of FDG PET/ CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann Nucl Med. 2011; 25(7):501-10.
22
Kim YI, Kim SK, Lee JW, Lee SM, Kim TS. Ovarian mass mimicking malignancy: a case report. Nucl Med Mol Imaging. 2010; 44(4):290-3.
23
Schaefferkoetter J, Ouyang J, Rakvongthai Y, Nappi C, El Fakhri G. Effect of time-of-flight and point spread function modeling on detectability of myocardial defects in PET. Med Phys. 2014; 41(6):062502.
24
Brambilla M, Cannillo B, Dominietto M, Leva L, Secco C, Inglese E. Characterization of ordered-subsets expectation maximization with 3D post-reconstruction Gauss filtering and comparison with filtered backprojection in 99mTc SPECT. Ann Nucl Med. 2005;19(2):75-82.
25
Nagamachi S, Wakamatsu H, Kiyohara S, Fujita S, Futami S, Arita H, et al. The reproducibility of deep-inspiration breath-hold (18)F-FDG PET/CT technique in diagnosing various cancers affected by respiratory motion. Ann Nucl Med. 2010;24(3):171-8.
26
Yukutake M, Sasaki T, Serikawa M, Minami T, Okazaki A, Ishigaki T, et al. The effect of respiratory-gated positron emission tomography/computed tomography in patients with pancreatic cancer. Hell J Nucl Med. 2014;17(1):31-6.
27
ORIGINAL_ARTICLE
Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/ Cotswolds Meeting Criteria
Objective(s): Post-treatment evaluations by CT/MRI (based on the International Working Group/ Cotswolds meeting guidelines) and PET (based on Revised Response Criteria), were examined in terms of progression-free survival (PFS) in patients with malignant lymphoma (ML). Methods: 79 patients, undergoing CT/MRI for the examination of suspected lesions and whole-body PET/CT before and after therapy, were included in the study during April 2007-January 2013. The relationship between post-treatment evaluations (CT/MRI and PET) and PFS during the follow-up period was examined, using Kaplan-Meier survival analysis. The patients were grouped according to the histological type into Hodgkin’s lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and other histological types. The association between post-treatment evaluations (PET or PET combined with CT/ MRI) and PFS was examined separately. Moreover, the relationship between disease recurrence and serum soluble interleukin-2 receptor, lactic dehydrogenase, and C-reactive protein levels was evaluated before and after the treatment. Results: Patients with incomplete remission on both CT/MRI and PET had a significantly shorter PFS, compared to patients with complete remission on both CT/MRI and PET and those exhibiting incomplete remission on CT/MRI and complete remission on PET (P<0.001). Post-treatment PET evaluations were strongly correlated with patient outcomes in cases with HL or DLBCL (P<0.01) and other histological types (P<0.001). In patients with HL or DLBCL, incomplete remission on both CT/MRI and PET was associated with a significantly shorter PFS, compared to patients with complete remission on both CT/MRI and PET (P<0.05) and those showing incomplete remission on CT/MRI and complete remission on PET (P<0.01). In patients with other histological types, incomplete remission on both CT/MRI and PET was associated with a significantly shorter PFS, compared to cases with complete remission on both CT/MRI and PET (P<0.001). None of the serum parameters differed significantly between recurrent and non-recurrent cases. Conclusion: Post-treatment PET evaluations were well correlated with the outcomes of patients with ML, exhibiting FDG uptake. Among patients with HL or DLBCL, a post-treatment complete remission on PET was predictive of a relatively long PFS. For predicting the prognosis of patients with other histological types, a combination of CT/MRI and PET, rather than PET alone, is recommended.
https://aojnmb.mums.ac.ir/article_4395_c6c5080fd10e31319a9dbf12eafffb07.pdf
2015-07-01
91
98
10.7508/aojnmb.2015.02.004
FDG-PET
CT
MRI
Malignant lymphoma
Prognosis
Kayako
Isohashi
isohashi-k@tracer.med.osaka-u.ac.jp
1
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
LEAD_AUTHOR
Mitsuaki
Tatsumi
m-tatsumi@radiol.med.osaka-u.ac.jp
2
Department of Radiology, Osaka University Graduate School of Medicine
AUTHOR
Hiroki
Kato
kato@tracer.med.osaka-u.ac.jp
3
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
AUTHOR
Kentaro
Fukushima
kfukushi@bldon.med.osaka-u.ac.jp
4
Department of Hematology and Oncology , Osaka University Graduate School of Medicine
AUTHOR
Tetsuo
Maeda
mtetsuo@bldon.med.osaka-u.ac.jp
5
Department of Hematology and Oncology , Osaka University Graduate School of Medicine
AUTHOR
Tadashi
Watabe
watabe@tracer.med.osaka-u.ac.jp
6
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
AUTHOR
Eku
Shimosegawa
eku@tracer.med.osaka-u.ac.jp
7
Department of Molcular Imaging in Medicine,Osaka University Graduate School of Medicine
AUTHOR
Yuzuru
Kanakura
kanakura@bldon.med.osaka-u.ac.jp
8
Department of Hematology and Oncology , Osaka University Graduate School of Medicine
AUTHOR
Jun
Hatazawa
hatazawa@tracer.med.osaka-u.ac.jp
9
Immunology Frontier Research Center, Osaka University, Osaka, Japan
AUTHOR
1. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non- Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244-53.
1
2. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–6.
2
3. Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009;50(Suppl 1):1-10.
3
4. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50:(Suppl 1):21-30.
4
5. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206(2):475-81.
5
6. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998;25(7):721-8.
6
7. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology. 1994;190(1):111-6.
7
8. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, et al. 2-(fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicentertrial.Cancer. 2001;91(5):889-99.
8
9. Rhodes MM, Delbeke D, Whitlock JA, Martin W, Kuttesch JF, Frangoul HA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol.2006;28(5):300-6.
9
10. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology.2005;237(3):1038-45.
10
11. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.J Clin Oncol. 2005;23(21):4652-61.
11
12. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104(5):1066-74.
12
13. Gallamini A. Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica. 2010;95(7):1046-8.
13
14. Isohashi K, Tatsumi M, Higuchi I, Inoue A, Nakajo K, Ishikawa J, et al. 18F-FDG-PET in patients with malignant lymphoma having long-term followup: staging and restaging, and evaluation of treatment response and recurrence. Ann Nucl Med. 2008;22(9):795-802.
14
15. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised ResponseCriteria for Malignant Lymphoma. J Clin Oncol. 2007;25(5):579-86.
15
16. Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after firstline chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(2):307-15.
16
17. Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun. 1999;20(1):13-20.
17
18. Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, et al. Role of [18F] fluorodeoxyglucose positron emission tomography scan in the followup of lymphoma. J Clin Oncol. 2009;27(11):1781-7.
18
19. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-8.
19
20. Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD. End-Therapy Positron EmissionTomography for Treatment Response Assessment in FollicularLymphoma: A SystematicReview and Meta-analysis. Clin Cancer Res. 2013;19(23):1–12.
20
21. Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, et.al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 2012;91(5):705-14.
21
22. Shimomura Y, Tsurumi H, Sawada M, Yamada T, Hara T, Fukuno K, et.al. Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma. RinshoKetsueki.1999;40(8):639-45.
22
23. Yoshizato T, Nannya Y, Imai Y, Ichikawa M, Kurokawa M. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13(4):410-6.
23
24. Wieland A, Kerbi R, Berqhold A, Schwinger W, Mann G, Urban C.C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol. 2003;41(1):21-5.
24
25. Bakhshi S, Radhakrishnan V, Sharma P, Kumar R, Thulkar S, Vishnubhatla S, et al. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study. Radiology. 2012;262(3):956-68.
25
26. Kelly KM, Hodgson D, Appel B, Chen L, Cole PD, Horton T, et al. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2013;60(6):972-8.
26
27. Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med. 2011;25(10):701-16.
27
28. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11(11):2101–11.
28
29. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC.18F-fluorodeoxyglucose
29
positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006;91(4):522-9.
30
30. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932-45.
31
31. Srinivas SM, Dhurairaj T, Basu S, Bural G, Surti S, Alavi A. A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med.2009;23(4):341-8.
32
32. Lu Z, Lin M, Downe P, Chong S, Ling S. The prognostic value of mid- and post-treatment [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med.2014;28(8):805-11.
33
33. Lopci E, Zanoni L, Chiti A, Fonti C, Santi I, Zinzani PL, et al. FDGPET/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2012;39(5):864-71.
34
34. Alcantara M, Dupuis J, Mareschal S, Julian A, Cottereau AS, Becker S, et al. PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. Eur J Nucl Med Mol Imaging. 2015;
35
42(2):215-21.
36
35. Bodet-Milin C, Eugène T, Gastinne T, Frampas E, Le Gouill S, Kraeber-Bodéré F. FDG-PET in Follicular Lymphoma Management.J Oncol. 2012;2012:370272.
37
36. Wu X, Pertovaara H, Korkola P, Vornanen M, Järvenpää R, Dastidar P, et al. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma. Acta Oncol. 2014;53(8):1093-9.
38
37. Tatsumi M, Sugahara H, Higuchi I, Fukunaga H, Nakamura H, Kanakura Y, et al. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values. Int J Clin Oncol. 2009;14(2):150-8.
39
ORIGINAL_ARTICLE
Preparation and Quality Control of 68Ga-Citrate for PET Applications
Objective(s): In nuclear medicine studies, gallium-68 (68Ga) citrate has been recently known as a suitable infection agent in positron emission tomography (PET). In this study, by applying an in-house produced 68Ge/68Ga generator, a simple technique for the synthesis and quality control of 68Ga-citrate was introduced; followed by preliminary animal studies. Methods: 68GaCl3 eluted from the generator was studied in terms of quality control factors including radiochemical purity (assessed by HPLC and RTLC), chemical purity (assessed by ICP-EOS), radionuclide purity (evaluated by HPGe), and breakthrough. 68Ga-citrate was prepared from eluted 68GaCl3 and sodium citrate under various reaction conditions. Stability of the complex was evaluated in human serum for 2 h at 370C, followed by biodistribution studies in rats for 120 min. Results: 68Ga-citrate was prepared with acceptable radiochemical purity (>97 ITLC and >98% HPLC), specific activity (4-6 GBq/mM), chemical purity (Sn, FeConclusion: This study demonstrated the possible in-house preparation and quality control of 68Ga-citrate, using a commercially available 68Ge/68Ga generator for PET imaging throughout the country.
https://aojnmb.mums.ac.ir/article_4188_cc76083fbb05e7cbbf95f8021186db46.pdf
2015-07-01
99
106
10.7508/aojnmb.2015.02.005
68Ge/68Ga Generator
68Ga-Citrate
Biodistribution
Quality Control
Ayuob
Aghanejad
ayuob.aghanejad@gmail.com
1
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
AUTHOR
Amir
Jalilian
ajalili@aeoi.org.ir
2
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
LEAD_AUTHOR
Khosro
Ardaneh
aardaneh@yahoo.com
3
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
AUTHOR
Fatemeh
Bolourinovin
fbolori@nrcam.org
4
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
AUTHOR
Hassan
Yousefnia
hasan_usefnia@yahoo.com
5
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
AUTHOR
Ali
Bahrami-Samani
ali.samani@gmail.com
6
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
AUTHOR
Firestone RB, Shirley VS, Baglin CM, Zipkin J. Table of isotopes. 8th edition. New York: John Wiley and Sons; 1996. p. 1447.
1
DDEP, Decay Data Evaluation Project Data. http:// www.nucleide.org/DDEP_WG/DDEPdata.htm (2008).
2
Burleson RL, Johnson MC, Head H. Scintigraphic demonstration of experimental abscesses with intravenous 67Ga citrate and 67Ga labeled blood leukocytes. Ann Surg. 1973; 178(4):446-52.
3
Jalilian AR, Novinrooz A, Motamedi-Sedeh F, Moradkhani S, Rajamand AA, Solati J. Evaluation of [67Ga]Citrate in The Detection of Various Microorganism Infections in Animal Models. Iran J Nucl Med. 2009;17(2):34-41.
4
Nanni C, Errani C, Boriani L, Fantini L, Ambrosini V, Boschi S, et al. 68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. J Nucl Med. 2010;51(12):1932-6.
5
Kumar V, Boddeti DK, Evans SG, Angelides S. (68) Ga-Citrate-PET for diagnostic imaging of infection in rats and for intra-abdominal infection in a patient. Curr Radiopharm. 2012;5(1):71-5.
6
Jensen SB, Nielsen KM, Mewis D, Kaufmann J. Fast and simple one-step preparation of 68Ga citrate for routine clinical PET. Nucl Med Commun. 2013; 34(8):806-12.
7
Rizzello A, Di Pierro D, Lodi F, Trespidi S, Cicoria G, Pancaldi D, et al. Synthesis and quality control of 68Ga citrate for routine clinical PET. Nucl Med Commun. 2009;30(7):542-5.
8
Vorster M, Mokaleng B, Sathekge MM, Ebenhan T. A modified technique for efficient radiolabeling of 68Ga-citrate from a SnO2-based 68Ge/68Ga generator for better infection imaging. Hell J Nucl Med. 2013;16(3):193-8.
9
Kumar V, Boddeti DK, Evans SG, Angelides S. (68) Ga-Citrate-PET for diagnostic imaging of infection in rats and for intra-abdominal infection in a patient. Current Radiopharmaceut. 2011; 5(1):71-5.
10
Silvola JM, Laitinen I, Sipilä HJ, Laine VJ, Leppänen P, Ylä-Herttuala S, et al. Uptake of gallium-68 in atherosclerotic plaques in LDLR-/- ApoB100/100 mice. EJNMMI Res. 2011;1(1):14.
11
Jalilian AR, Bineshmarvasti M, Sardari S. Application of radioisotopes in Inflammation. Curr Med Chem. 2006;13(8):959-65.
12
Fazaeli Y, Jalilian AR, Ardaneh K, Rahiminejad A, Bolourinovin F, Moradkhani S, et al. Development of a 68Ga-fluorinated porphyrin complex as a possible PET imaging agent. Nucl Med Mol Imaging. 2012; 46(1):20-6.
13
Jalilian AR, Rowshanfarzad P, Sabet M, Novinrooz A, Raisali G. Preparation of [66Ga]Bleomycin Complex as a Possible PET Radiopharmaceutical. J Radioanal Nucl Chem. 2005; 264: 617-21.
14
Kamada M. Distribution of 67Ga-citrate in tumor tissues and various organs. Radioisotopes (Tokyo). 1978; 27(7):390-396.
15
Gallium (68Ga) endotreotide injection. Pharmeuropa. 2011; 23(2):310-3.
16
Jalilian AR, Yousefnia H, Zolghadri S, Khoshdel MR, Bolourinovin F, Rahiminejad A. Development of radiogallium–ethylenecysteamine cysteine complex as a possible renal imaging agent. J Radioanal Nucl Chem. 2010; 284:49–54
17
ORIGINAL_ARTICLE
Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
Objective(s): Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 (90Y) and lutetium-177 (177Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We report on our one year experience with an automated radiopharmaceutical synthesis system.Methods: All syntheses were carried out using the Eckert & Ziegler Eurotope’s Modular-Lab Pharm Tracer® automated synthesis system. All materials and methods used were followed as instructed by the manufacturer of the system (Eckert & Ziegler Eurotope, Berlin, Germany). Sterile, GMP-certified, no-carrier added (NCA) 177Lu was used with GMPcertifiedpeptide. An audit trail was also produced and saved by the system. The quality of the final product was assessed after each synthesis by ITLCSG and HPLC methods.Results: A total of 17 [177Lu]-DOTATATE syntheses were performed between August 2013 and December 2014. The amount of radioactive [177Lu]-DOTATATE produced by each synthesis varied between 10-40 GBq and was dependant on the number of patients being treated on a given day. Thirteen individuals received a total of 37 individual treatment administrations in this period. There were no issues and failures with the system or the synthesis cassettes. The average radiochemical purity as determined by ITLC was above 99% (99.8 ± 0.05%) and the average radiochemical purity as determined by HPLC technique was above 97% (97.3 ± 1.5%) for this period.Conclusions: The automated synthesis of [177Lu]-DOTATATE using Eckert & Ziegler Eurotope’s Modular-Lab Pharm Tracer® system is a robust, convenient and high yield approach to the radiolabelling of DOTATATE peptide benefiting from the use of NCA 177Lu and almost negligible radiation exposure of the operators.
https://aojnmb.mums.ac.ir/article_4497_e7f69c0958b961db59cc29bad4a19495.pdf
2015-07-01
107
115
10.7508/aojnmb.2015.02.006
Lutetium-DOTATATE
Neuroendocrine Tumours
automated synthesis
Peptide Receptor Radionuclide Therapy
Alireza
Aslani
alireza.aslani@health.nsw.gov.au
1
Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia
LEAD_AUTHOR
Graeme
Snowdon
graeme.snowdon@health.nsw.gov.au
2
Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia
AUTHOR
Dale
Bailey
dale.bailey@sydney.edu.au
3
Faculty of Health Sciences, University of Sydney, Sydney, Australia
AUTHOR
Geoffrey
Schembri
geoffschembri@gmail.com
4
Sydney Medical School, University of Sydney, Sydney, Australia
AUTHOR
Elizabeth
Bailey
elizabeth.bailey2@health.nsw.gov.au
5
Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia
AUTHOR
Pavlakis
Nick
nick.pavlakis@sydney.edu.au
6
Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia
AUTHOR
Paul
Roach
paul.roach@sydney.edu.au
7
Sydney Medical School, University of Sydney, Sydney, Australia
AUTHOR
1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97(4):934-59.
1
2. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003; 24(4):389-427.
2
3. Reubi JC, Waser B. Concomitant expression of several peptide receptors in Neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003; 30(5):781-93.
3
4. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq [90Y]-DOTATOC. J Nucl Med. 2002; 43(5):610-6.
4
5. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177]Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003; 30(3):417-22.
5
6. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu]-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23(12):2754-62.
6
7. Hofman MS, Hicks RJ. Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized? Eur J Nucl Med Mol Imaging. 2014; 41(2):211-3.
7
8. Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatinbased radiopeptide therapy with [90Y-DOTA]-TOC
8
versus [90Y -DOTA]-TOC plus [177Lu -DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012; 30(10):1100-6.
9
9. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu -DOTAOTyr3] octreotate: comparison with [111In-DTPA]octreotide in patients. Eur J Nucl Med. 2001; 28(9):1319-25.
10
10. Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun. 2007; 28(11):870-5.
11
11. Ocak M, Antretter M, Knopp R, Kunkel F, Petrik M, Bergisadi N, et al. Full automation of (68)Ga labeling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot. 2010; 68(2):297-302.
12
12. Petrik M, Knetsch PA, Knopp R, Imperato G, Ocak M, von Guggenberg E, et al. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nucl Med Commun. 2011; 32(10):887-95.
13
13. De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm. 2012; 27(1):72-6.
14
14. Barber TW, Hofman MS, Thomson BN, Hicks RJ. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012; 38(1):64-71.
15
15. Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA, Roach PJ. Gallium-68 DOTATATE production with automated PET radiopharmaceutical synthesis system: A three year experience. Asia Oceania J Nucl Med Biol. 2014; 2(2):75-86.
16
16. Bakker WH, Breeman WA, Kwekkeboom DJ, DeJong LC, Krenning EP. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3] octreotate. Q J Nucl Med Mol Imaging. 2006; 50(4):265-71.
17
17. Breeman WA, de Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003; 30(6):917-20.
18
ORIGINAL_ARTICLE
FDG-PET/CT and CT findings of a benign solitary fibrous tumor of the kidney: correlation with pathology
Herein, we report the F-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) findings of a benign solitary fibrous tumor (SFT) of the kidney. The patient was a 63-year-old woman with a mass in the right kidney (10×9.7 cm), incidentally found on CT images. The CT scan showed a lobulated tumor arising from the hilum of the right kidney. The tumor consisted of two components with different patterns of enhancement. Most of the tumor demonstrated moderate enhancement from the corticomedullary to nephrographic phase. A small nodular component at the caudal portion of the tumor showed avid enhancement in the corticomedullary phase and rapid washout in the nephrographic phase in contrast-enhanced CT. FDG-PET/CT was performed and showed weak FDG accumulation (SUVmax=2.30 and 1.91 in the main and small caudal components). Although renal cell carcinoma was preoperatively diagnosed, histopathological examination revealed renal SFT, with no malignant potential. Therefore, when a renal tumor with contrast-medium enhancement and low FDG accumulation is demonstrated, SFT should be considered as a differential diagnosis in addition to renal cell carcinoma.
https://aojnmb.mums.ac.ir/article_3516_b3d5e8b55e5b3b85bfb3730cef9336e4.pdf
2015-07-01
116
119
10.7508/aojnmb.2015.02.007
Kidney
solitary fibrous tumor
benign
FDG-PET/CT
Reiko
Nakajima
reiko726reiko@gmail.com
1
Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Koichiro
Abe
abe.koichiro@twmu.ac.jp
2
Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women’s Medical University, Tokyo, Japan
LEAD_AUTHOR
Tsunenori
Kondo
tkondo@kc.twmu.ac.jp
3
Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Yoji
Nagashima
nagashima.yoji@twmu.ac.jp
4
Department of Surgical Pathology, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Ken
Kimura
kimura.ken@twmu.ac.jp
5
Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Kenji
Fukushima
kfukush4@me.com
6
Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Mitsuru
Momose
mmomose@rad.twmu.ac.jp
7
Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Chisato
Kondo
pkondou@rad.twmu.ac.jp
8
Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Kazunari
Tanabe
tanabe@kc.twmu.ac.jp
9
Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Shuji
Sakai
sakai@rad.twmu.ac.jp
10
Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women’s Medical University, Tokyo, Japan
AUTHOR
Gold JS, Antonescu CR, Hajdu C, Ferrone CR, Hussain M, Lewis JJ, et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94(4):1057- 68.
1
Znati K, Chbani L, El Fatemi H, Harmouch T, Kamaoui I, Tazi F, et al. Solitary fibrous tumor of the kidney: a case report and review of the literature. Rev Urol. 2007;9(1):36-40.
2
Mearini E, Cochetti G, Barillaro F, Fatigoni S, Roila F. Renal malignant solitary fibrous tumor with single lymph node involvement: report of unusual metastasis and review of the literature. Onco Targets Ther. 2014;7:679-85.
3
Khater N, Khauli R, Shahait M, Degheili J, Khalifeh I, Aoun J. Solitary fibrous tumors of the kidneys: presentation, evaluation, and treatment. Urol Int. 2013;91(4):373-83.
4
Katabathina VS, Vikram R, Nagar AM, Tamboli P, Menias CO, Prasad SR. Mesenchymal neoplasms of the kidney in adults: imaging spectrum with radiologic-pathologic correlation. Radiographics. 2010;30(6):1525-40.
5
Kuroda N, Ohe C, Sakaida N, Uemura Y, Inoue K, Nagashima Y, et al. Solitary fibrous tumor of the kidney with focus on clinical and pathobiological aspects. Int J Clin Exp Pathol. 2014;7(6):2737-42.
6
Gengler C, Guillou L. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology. 2006;48(1):63-74.
7
Cheah AL, Billings SD, Goldblum JR, Carver P, Tanas MZ, Rubin BP. STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics. Pathology. 2014;46(5):389-95.
8
Bertagna F, Motta F, Bertoli M, Bosio G, Fisogni S, Tardanico R, et al. Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma. Nucl Med Rev Cent East Eur. 2013;16(1):3-8.
9
Yan J, Mann F, Lewis D, Eary JF. Solitary fibrous tumor: WHO classification, histopathological correlation contribution to the Radiology-Pathology Conference, FDG PET-CT imaging, and biological behaviors. Clin Imaging. 2013;37(5):977-8.
10
Song L, Zhang W, Zhang Y. 18F-FDG PET/CT Imaging of Malignant Hepatic Solitary Fibrous Tumor. Clin Nucl Med. 2014;39(7):662-4.
11
Lococo F, Cafarotti S, Treglia G. Is 18F-FDG-PET/CT really able to differentiate between malignant and benign solitary fibrous tumor of the pleura? Clin Imaging. 2013;37(5):976-7.
12
Treglia G, Oragano L, Fadda G, Raffaelli M, Lombardi CP, Castaldi P, et al. A rare case of solitary fibrous tumor of the adrenal gland detected by (18)F-FDG PET/CT. Clin Nucl Med. 2014;39(5):475-7.
13
Dong A, Zuo C, Wang Y, Cui Y. Enhanced CT and FDG PET/CT in malignant solitary fibrous tumor of the lung. Clin Nucl Med. 2014;39(5):488-91.
14
ORIGINAL_ARTICLE
Dual-time-point FDG-PET/CT Imaging of Temporal Bone Chondroblastoma: A Report of Two Cases
Temporal bone chondroblastoma is an extremely rare benign bone tumor. We encountered two cases showing similar imaging findings on computed tomography (CT), magnetic resonance imaging (MRI), and dual-time-point 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT. In both cases, CT images revealed temporal bone defects and sclerotic changes around the tumor. Most parts of the tumor showed low signal intensity on T2- weighted MRI images and non-uniform enhancement on gadolinium contrast-enhanced T1-weighted images. No increase in signal intensity was noted in diffusion-weighted images. Dual-time-point PET/CT showed markedly elevated 18F-FDG uptake, which increased from the early to delayed phase. Nevertheless, immunohistochemical analysis of the resected tumor tissue revealed weak expression of glucose transporter-1 and hexokinase II in both tumors. Temporal bone tumors, showing markedly elevated 18F-FDG uptake, which increases from the early to delayed phase on PET/CT images, may be diagnosed as malignant bone tumors. Therefore, the differential diagnosis should include chondroblastoma in combination with its characteristic findings on CT and MRI.
https://aojnmb.mums.ac.ir/article_3918_6a637697c253cec1cb9364810c1b06de.pdf
2015-07-01
120
124
10.7508/aojnmb.2015.02.008
temporal bone chondroblastoma
dual-time-point FDG-PET/CT
MRI
Akira
Toriihara
trihmrad@tmd.ac.jp
1
Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Yushima, Bunkyoku,
Tokyo, Japan
LEAD_AUTHOR
Atsunobu
Tsunoda
atsunoda@me.com
2
Department of Otolaryngology, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo, Japan
AUTHOR
Akira
Takemoto
takepth1@tmd.ac.jp
3
Department of Human Pathology, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo, Japan
AUTHOR
Kazunori
Kubota
kbtmrad@tmd.ac.jp
4
Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Yushima, Bunkyoku,
Tokyo, Japan
AUTHOR
Youichi
Machida
mcdmrad@tmd.ac.jp
5
Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Yushima, Bunkyoku,
Tokyo, Japan
AUTHOR
Ukihide
Tateishi
ttisdrnm@tmd.ac.jp
6
Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Yushima, Bunkyoku,
Tokyo, Japan
AUTHOR
1. Dahlin DC, Ivins JC. Benign chondroblastoma. A study of 125 cases. Cancer. 1972;30:401-13.
1
2. Reid LB, Wong DS, Lyons B. Chondroblastoma of the temporal bone: a case series, review, and suggested management strategy. Skull Base Rep. 2011;1:71-82.
2
3. Hatano M, De Donato G, Falcioni M, Sanna M. Chondroblastoma of the temporal bone. Acta Otolaryngol. 2011;131:890-5.
3
4. Bian LG, Sun QF, Zhao WG, Shen JK, Tirakotai W, Bertalanffy H. Temporal bone chondroblastoma: a review. Neuropathology. 2005;25:159-64.
4
5. de Silva MV, Reid R. Chondroblastoma: varied histologic appearance, potential diagnostic pitfalls, and clinicopathologic features associated with local recurrence. Ann Diagn Pathol. 2003;7:205-13.
5
6. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001;219:774-7.
6
7. Hamada K, Ueda T, Tomita Y, Higuchi I, Inoue A, Tamai N, et al. False positive 18F-FDG PET in an ischial chondroblastoma; an analysis of glucose transporter 1 and kexokinase II expression. Skeletal Radiol. 2006;35:306-10.
7
8. Tian R, Su M, Tian Y, Li F, Li L, Kuang A, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol. 2009;38:451-8.
8
9. Iizuka T, Furukawa M, Ishii H, Kasai M, Hayashi C, Arai H, et al. Giant cell tumor of the temporal bone with direct invasion into the middle ear and skull base: a case report. Case Report Otolaryngol. 2012; 2012: 690148.
9
10. Ma Y, Liu L, Huang D, Han D, Wang J, Wu W, et al. Diagnosis and treatment of giant cell granuloma of the temporal bone: report of eight cases. Acta Otolaryngol. 2012;132:657-62.
10
ORIGINAL_ARTICLE
A Report on IAEA/RCA C-7RAS 004-061/6 Training Course in Chiba, Japan in 2014
The C7-RAS 6/061-004 training course by the International Atomic Energy Agency/Regional Cooperative Agreement (IAEA/RCA) was held in Chiba in 2014. The syllabus, pre- and post-course evaluations, and survey questionnaire results were assembled in this course. The post-course evaluation, including 32 questions similar to the pre-course evaluation, was performed right after the end of the final educational lecture. The mean score showed an improvement, with the score rising from 57.0 points at the beginning to 66.5 points at the end. Among 22 trainees, the greatest score was in a higher range, with an improvement from 82 points at the beginning to 88 points at the end. The grading distribution, with regard to the training course, was as follows: excellent (68.2%), good (31.8%), average (0%), fair (0%), and poor (0%). This report on the training course, held in Chiba in 2014, will contribute to the future global plans of IAEA/RCA. Continuous training courses in member states are required to decrease the present disparities in the knowledge level, instrumentation, and human resources.
https://aojnmb.mums.ac.ir/article_4064_b91ff4142ce825877a03cc1e9039302b.pdf
2015-07-01
125
128
10.7508/aojnmb.2015.02.009
training course
PET/CT
SPECT/CT
oncology
Shigeru
Kosuda
nucleark@ndmc.ac.jp
1
Department of Radiology, National Defense Medical College
LEAD_AUTHOR
Tsuneo
Saga
saga@nirs.go.jp
2
Molecular Imaging Center, National Institute of Radiological Sciences
AUTHOR
Diana
Paez
d.paez@iaea.org
3
Nuclear Medicine and Diagnostic Imaging, Division of Human Health, Department of Nuclear Sciences and
Applications, IAEA
AUTHOR
1. World Health Organization Media Center. Cancer: fact sheet no. 297. 2012. http//www.who.int/medicentre/factsheets/fs297/en/index.html.
1
2. NUMDAB (Nuclear Medicine DAtaBase). International Atomic Energy Agency. http//nuclear medicine.iaea.org/.
2
3. Dondi M, Kashyap R, Paez D, Pascual T, Zaknun J, Bastos FM, et al. Trends in nuclear medicine in developing countries. J Nucl Med. 2011;52 Supple2:16S-23S.
3
4. Kosuda S, Alam F, Yao Z, Kardinah K, Lee BN, Enkhthuya B, et al. Report on the current nuclear medicine status of the Asian member states from the initial cooperative project meeting (RAS6061/9001/01) of International Atomic
4
Energy Agency/regional cooperative agreement (IAEA/RCA). Austral Asian J Cancer. 2013;12:135-45.
5
5. Sabih De. The Asian nuclear medicine board (ANMB); why do we need it? Asia Oceania J Nucl Med Biol. 2013;1:1-3.
6